ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.
